Research programme: claudin antagonists - Adherex Technologies
Latest Information Update: 23 Feb 2011
At a glance
- Originator Adherex Technologies
- Mechanism of Action Cell adhesion molecule inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 25 Aug 2006 No development reported - Preclinical for Cancer in Canada (unspecified route)
- 18 May 2004 Preclinical trials in Cancer in Canada (unspecified route)